CLOUDBREAK PHARMA INC. 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 撥 康 視 雲 製 藥 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：2592） 更改香港主要營業地點 撥康視雲製藥有限公司（「本公司」）董事會（「董事」）謹此宣佈，本公司之香港 主要營業地點改為香港九龍海港城港威大廈2座23A樓23A11室。 * 僅供識別 承董事會命 撥康視雲製藥有限公司 * 主席、執行董事兼道首席執行官 NI Jinsong博士 香港，2025年8月26日 於本公告日期，本公司董事會包括：(i)執行董事Ni Jinsong博士、Dinh Son Van先生、Yang Rong博 士；(ii)非執 行董事Li Jun Zhi博士、曹旭先生及夏志東先生；及(iii)獨立非執行董事賴顯榮先生、廖仲敏先生及聶四江女士。 本公司之電話及網址維持不變。 ...

拨康视云-B(02592)发布公告，集团预计将于截至2025年6月30日止六个月期间取得除所得税前综合溢利 净额不低于450万美元，相较于集团截至2024年6月30日止六个月期间除所得税前综合亏损净额约5210万 美元，属转亏为盈。 倘未计及上述可换股可赎回优先股的公平值正值变动(过往期间：可换股可赎回优先股的公平值负值变 动)，集团预期于报告期间取得除所得税前综合亏损净额不少于3280万美元，较过往期间的约2530万美 元增加约29.6%。 公司相信，有关预期除所得税前综合亏损净额转为除所得税前综合溢利净额主要归因于(其中包括)可换 股可赎回优先股的公平值正值变动约为3840万美元，而于过往期间可换股可赎回优先股的公平值负值变 动则约为2680万美元，反映截至2025年6月30日的一次性公平值调整。如公司日期为2025年6月24日的招 股章程所披露：(a)所有可换股可赎回优先股于公司股份在2025年7月3日于联交所主板完成首次公开发 售及上市后自动转换为公司普通股;(b)于可换股可赎回优先股在上市后自负债重新分类及重新指定为权 益后，公司预期未来不会就可换股可赎回优先股确认任何其他公平值变动亏损或收益。 ...

智通财经APP讯，拨康视云-B(02592)发布公告，集团预计将于截至2025年6月30日止六个月期间取得除 所得税前综合溢利净额不低于450万美元，相较于集团截至2024年6月30日止六个月期间除所得税前综合 亏损净额约5210万美元，属转亏为盈。 公司相信，有关预期除所得税前综合亏损净额转为除所得税前综合溢利净额主要归因于(其中包括)可换 股可赎回优先股的公平值正值变动约为3840万美元，而于过往期间可换股可赎回优先股的公平值负值变 动则约为2680万美元，反映截至2025年6月30日的一次性公平值调整。如公司日期为2025年6月24日的招 股章程所披露：(a)所有可换股可赎回优先股于公司股份在2025年7月3日于联交所主板完成首次公开发 售及上市后自动转换为公司普通股;(b)于可换股可赎回优先股在上市后自负债重新分类及重新指定为权 益后，公司预期未来不会就可换股可赎回优先股确认任何其他公平值变动亏损或收益。 倘未计及上述可换股可赎回优先股的公平值正值变动(过往期间：可换股可赎回优先股的公平值负值变 动)，集团预期于报告期间取得除所得税前综合亏损净额不少于3280万美元，较过往期间的约2530万美 元增加 ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 本公告乃由撥康視雲製藥有限公司（「* 本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交易所 有限公司證券上市規則（「上市規則」）第13.09條及證券及期貨條例（香港法例第571章）第XIVA部項下 的內幕消息條文（定義見上市規則）作出。 本公司董事（「董事」）會（「董事會」）欣然告知本公司股東（「股東」）及潛在投資者，根據對本集團截至 2025年6月30日止六個月期間（「報告期間」）未經審核綜合管理賬目（「管理賬目」）的初步評估及董事會 目前可獲得的其他相關資料，本集團預計將於報告期間錄得除所得稅前綜合溢利淨額不低於4.5百萬 美元，相較於本集團截至2024年6月30日止六個月期間（「過往期間」）除所得稅前綜合虧損淨額約52.1 百萬美元，屬轉虧為盈。 本公司相信，有關預期除所得稅前綜合虧損淨額轉為除所得稅前綜合溢利淨額主要歸因於（其中包 括）可換股可贖回優先股的公平值正值變動約為3 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CLOUDBREAK PHARMA INC. 撥 康 視 雲 製 藥 有 限 公 司 * 董事會會議日期 撥康視雲製藥有限公司（「本公司」）董事會（「董事」）及其附屬公司(「本集團」) 謹此宣佈，將於二零二五年八月二十九日（星期五）舉行董事會會議，藉以（其中包 括）考慮並批准本集團截至二零二五年六月三十日止六個月之未經審核之中期業績及 其刊發，以及考慮派發中期股息（如有）。 承董事會命 撥康視雲製藥有限公司 * 主席、執行董事兼道首席執行官 NI Jinsong博士 香港，2025年8月19日 於本公告日期，本公司董事會包括：(i)執行董事Ni Jinsong博士、Van Son Dinh先生、Yang Rong博 士；(ii)非執 行董事Li Jun Zhi博士、曹旭先生及夏志東先生；及(iii)獨立非執行董事賴顯榮先生、廖仲敏先生及聶四江女士。 * 僅供識別 （於開曼群島註冊成立的有限公司） （股份 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Cloudbreak Pharma Inc. 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 02592 說明 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 2,000,000,000 USD 0.0001 USD 200,000 增加 / 減少 (-) USD 本月底結存 2,000,000,000 USD 0.0001 USD 200,000 本月底法定/註冊股本總額： USD 200,000 備註： 本公司股份於2025年7月3日於香港聯合交易所有限公司主板上市。此處「上月底結存」所示的資料指「於2025年7月3日上市時的結存」。 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1 ...

Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange (HKEX) saw 11 companies submit applications for listing from June 30 to July 6, with no companies passing the listing hearing during this period. Additionally, 7 companies initiated their public offerings, and 5 new stocks were listed. Group 1: Companies Submitting Applications - Puxiang Health Holdings Limited is a leading provider of integrated medical and elderly care services in North China, ranking second in revenue among its peers and first in revenue growth from 2022 to 2024 [2] - Magnesium Health Technology Co., Ltd. focuses on innovative payment solutions for medical expenses, being the largest provider of innovative health insurance solutions in China by policy count [3] - Yangtuo Technology Inc. operates a trading and service platform for home care and nutrition products, holding a 10.1% market share in the low-tier market [4] - Xiamen Ruiwei Information Technology Co., Ltd. specializes in image intelligent analysis products and solutions, leveraging machine learning and computer vision technologies [5] - Zijin Gold International Limited is a leading global gold mining company, ranking ninth in gold reserves and eleventh in production as of 2024 [6] - EVE Energy Co., Ltd. is a leading lithium battery platform company, ranking first in China for consumer cylindrical battery shipments and second globally for energy storage battery shipments [7] - Zhejiang Yifei Intelligent Technology Co., Ltd. is a leading industrial robotics company in China, focusing on the light industry [8] - ChipMight Semiconductor Technology (Hangzhou) Co., Ltd. is a leading power semiconductor company, ranking second in the global OLED display PMIC market [9] - Beijing Tongrentang Medical Investment Co., Ltd. is the largest non-public Chinese medicine hospital group by outpatient and inpatient visits [11] - Shandong Linglong Tire Co., Ltd. is the largest OE tire manufacturer in China and the third largest globally [12] - Magnesium Holdings Limited is an innovative automotive technology company focused on AI-driven integrated domain control solutions [13] Group 2: Public Offerings and New Listings - Seven companies initiated their public offerings, including Anjii Foods, which had a subscription rate of 44.2 times for its public offering [14][15] - Other companies like Lens Technology and Fortior also initiated their public offerings with significant interest from cornerstone investors [16][19] - Five new stocks were listed, including Yunzhisheng, which saw a closing price increase of 44.59% on its first day [20][21][22][23] Group 3: Market Insights - The Hong Kong Stock Exchange raised over HKD 107 billion in the first half of 2025, with a 20% increase in the Hang Seng Index [24] - The biopharmaceutical sector has seen a resurgence, with 10 companies successfully listing in the first half of 2025, compared to only 12 for the entire previous year [25][26] - The total fundraising amount for the biopharmaceutical sector reached HKD 15.6 billion in the first half of 2025, indicating strong market interest [26][27]

Core Insights - The article provides an overview of the latest trends in domestic investment and financing events, highlighting key sectors and companies involved in significant funding rounds [3]. Group 1: Investment Overview - A total of 93 financing events were disclosed in the domestic primary market this week, an increase of 5 events compared to the previous week. Among these, 34 events disclosed financing amounts, with a total financing scale of 10.248 billion RMB, averaging 301 million RMB per event [5]. - The most active sectors in terms of financing events were intelligent manufacturing (21 events), artificial intelligence (19 events), and healthcare (9 events) [7]. Group 2: Sector Analysis - In terms of disclosed financing amounts, the energy and power sector led with a total financing scale of approximately 4.434 billion RMB. Notably, "Yongxiang Co., Ltd." completed nearly 4.916 billion RMB in Series A financing [8]. - The intelligent manufacturing sector followed, with a disclosed financing total of 2.603 billion RMB, including nearly 1 billion RMB in angel round financing for "Sunrise," a high-performance GPU developer [10]. Group 3: Regional Distribution - The disclosed investment events were primarily concentrated in Jiangsu (19 events), Guangdong (17 events), and Beijing (13 events) [14]. - Jiangsu reported a total financing of 1.645 billion RMB across 7 disclosed events, while Beijing had 1.750 billion RMB from 6 disclosed events [17]. Group 4: Stage Distribution - The majority of the disclosed investment events were early-stage (68 events), followed by growth-stage (19 events) and late-stage (6 events) [18]. Group 5: Major Financing Events - The article highlights significant financing events, including the acquisition of 100% of "Changqing Environmental Protection" by Huaxing New Energy for 401 million RMB, focusing on biomass power generation technology [36].

Group 1 - Shougang Longze has delayed its global offering and listing due to a civil lawsuit filed against it, which requires the company to provide more information to investors [1] - The company plans to issue a supplementary prospectus to update the listing timeline and related information [1] Group 2 - Hong Kong Stock Exchange has launched an order transmission service for its Integrated Fund Platform (IFP) to enhance efficiency in the fund distribution ecosystem [2] - The service integrates order processing for fund subscriptions and redemptions, welcoming 33 initial participants including distributors and fund companies [2] Group 3 - Eye care biotech company Bokan Vision Cloud-B saw its stock price drop significantly on its first trading day, closing down 38.61% from its IPO price of 10.1 HKD [3] - The decline may be attributed to market skepticism regarding its valuation and the current market environment for new listings [3] Group 4 - Anjoy Foods had a lackluster performance in the dark market, with its H-shares priced at 60 HKD and a total global offering of approximately 39.99 million shares [4] - Despite being the largest frozen food company in China with a market share of 6.6%, investor concerns about growth prospects and market competition may have impacted its initial reception [4]

Core Viewpoint - The ophthalmic biotech company Bolekang Shiyun-B (HK02592) officially listed on the Hong Kong Stock Exchange, experiencing a significant drop in share price on its first trading day, closing down 38.61% from its IPO price of HKD 10.1 per share [2][3] Company Overview - Bolekang Shiyun is an innovative clinical-stage ophthalmic biotech company focused on the discovery, development, and commercialization of first-in-class and best-in-class ophthalmic therapies [2] - The company was co-founded in 2015 by its current CEO, Ni Jinsong, who has extensive experience from Pfizer and Allergan [3] Financial Performance - Bolekang Shiyun has not yet commercialized any drugs and has reported losses of USD 66.84 million, USD 129 million, and USD 99.1 million for the years 2022, 2023, and 2024, respectively, totaling nearly USD 300 million over three years [3] - Research and development expenses are projected to increase from USD 15 million in 2022 to USD 38 million in 2024, with significant portions allocated to clinical trials for core products CBT-001 and CBT-009 [4] Product Development - The core products CBT-001 and CBT-009 are in the final stages of clinical trials, targeting pterygium and myopia in adolescents, with trials initiated in June 2022 and September 2023, respectively [3] - Other candidate drugs are in earlier stages of development, including two clinical-stage candidates and four preclinical candidates [3] IPO Details - The IPO was oversubscribed by 78.78 times in the public offering phase, with 12.12 million shares allocated, representing about 20% of the total offering [2] - The net proceeds from the global offering are approximately HKD 522 million, with plans to allocate 62.4% for ongoing clinical development of CBT-001 and related regulatory activities [5]